Logos Global Management LP
Position in DNTH — Dianthus Therapeutics, Inc. /DE/
CIK 1792126
San Francisco, CA
Position in DNTH
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$33,568,000
+$20,586,850 QoQ
Shares Held
400,000
+27.0% QoQ
Ownership
0.732%
of shares outstanding
% of Portfolio
1.73%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in DNTH Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Logos Global Management LP holds $1,835,814,678 across 59 Biotechnology names. DNTH ranks #17 (1.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
2,000,000 | $194,500,000 | |
| 2 | ERAS |
Erasca, Inc.
|
11,150,000 | $180,407,000 | |
| 3 | IDYA |
IDEAYA Biosciences, Inc.
|
3,450,000 | $114,954,000 | |
| 4 | PRAX |
Praxis Precision Medicines, Inc.
|
285,000 | $91,824,150 | |
| 5 | CNTA |
Centessa Pharmaceuticals plc
|
2,125,000 | $84,405,000 | |
| 6 | TERN |
Terns Pharmaceuticals, Inc.
|
1,500,000 | $79,080,000 | |
| 7 | ABVX |
Abivax S.A.
|
675,000 | $75,161,250 | |
| 8 | TNGX |
Tango Therapeutics, Inc.
|
3,000,000 | $62,760,000 |
All Filings in DNTH
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $33,568,000 | 400,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $12,981,150 | 315,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $7,870,000 | 200,000 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||